breakout, page-13

Strange day for AVX holders. $2.6m through and back to yesterday's closing price. Bue sky company and watchnig her intently.

Sydney - Thursday - June 4: (RWE Aust Business News) - Avexa
(ASX:AVX) has reviewed the 16 week data from its apricitabine (ATC) Phase
III clinical trial.
The Data Safety Monitoring Board reviewed the data and
recommended continuation of the study with the 800mg dose.
"We are delighted with the recommendation by the DSMB for the
continuation of the Phase III trial," chief executive Julian Chick said.
"The 800mg dose is considerably easier to formulate into fixed
dose combinations, thus increasing the commercial potential for ATC.
"Given ATC's excellent safety and activity profile, these results
allow us to move forward with increased confidence in ATC as a treatment
option for HIV patients."
Patients from the earlier Phase IIb study, which used the 800mg
ATC dose, have been successfully treated with ATC for up to three years.
This provides further evidence of the safety, efficacy, and
durability of 800mg ATC for the treatment of HIV.